important for CNS development and cognitive processes such as learning and memory 8 . Cleavage of p35 and 69 p39 by calpain produces truncated activators, p25 and p29, respectively 9 . These cleavage products have 70 increased protein stability and mislocalize in cells due to removal of an N-terminal myristoylation site 10 . In 71 neurons, p25 aberrantly activates Cdk5 and has been linked to neurotoxicity, neuronal injury, and 72 neurodegeneration 6 . 73 Recent research suggests the aberrant activation of Cdk5 in non-neuronal cells can usurp signaling 74 components involved in the cell cycle to drive proliferation 11 . Expression of Cdk5 and p35/p25 has been 75 shown for three types of neoplasms originating from neuroendocrine (NE) cells: medullary thyroid 76 carcinoma (MTC) 12 , small cell lung cancer (SCLC) 13 , and pituitary adenomas 14 . In MTC, inhibition of Cdk5 77 activity decreases rates of cell growth 12, 15 ; in SCLC and pituitary adenomas, it decreases migration and 78 invasion 16, 17 . Expression of p25 in thyroid C-cells produces MTC in mice 12 , in part through alteration of 79 traditional cell cycle regulatory components 18 . Here we show that Cdk5 and p35/p25 expression may be an 80 important driver of many types of NE cancer and that aberrant Cdk5 activity allows for a diagnostic-coupled 81 treatment strategy that targets this protein kinase. 83 To better understand the potential role of Cdk5 across multiple forms of NE malignancies, we assessed 84 expression of the kinase and its activating cofactors in different NE tumor and cancer types. Histological 85 analysis demonstrated that Cdk5 and p35/p25 are present throughout various human NE neoplasms including 86 MTC, pheochromocytoma (PHEO), pituitary adenoma, SCLC, pancreatic NE tumors, and gastrointestinal NE 87 tumors ( Fig. 1a ). Furthermore, these proteins are present in cell lines derived from multiple types of NE 88 neoplasms, including three human MTCs (TT, MTC-SK, and SIN-J), a human progenitor PHEO (hPheo1) 19 , a 89 human pancreatic carcinoid (BON), a rat insulinoma (INS), and two human SCLCs (H146 and H1184, Fig.   90 1b). Selective Cdk5 inhibition by Indolinone A (Indo A) blocked all human NE cancer cell growth more 91 potently than it affected normal human fibroblasts or rat INS cells ( Fig. 1c and Ext. Data Fig. 1a-h) . 92 Interestingly, the aberrant Cdk5 activator, p25, was present in all human cell lines derived from naturally occurring tumors but not the rat line generated using irradiation 20 (Fig. 1b ). Cells treated with Cdk5 inhibitors 94 typically showed flattening and smoothing of cell body consistent with a less malignant phenotype (Fig. 1d ). 95 Indo A inhibits Cdk5 activity with high affinity, but also affects Cdk4 21 . Importantly, the structurally 96 related Cdk4-specific inhibitor, Indo B, was 6.4-15.4 fold less potent at preventing human NE cell proliferation 97 ( Fig. 1c and Ext Data Fig. 1a-h) . Growth of multiple NE cancer cell lines was likewise blocked by the broad 98 spectrum Cdk inhibitors Roscovitine and Dinaciclib. CP681301, a selective inhibitor of both Cdk2 and Cdk5, 99 also blocked growth of NE cancer cells whereas the Cdk2 specific inhibitor CVT313 had a greatly reduced 100 effect (Ext. Data Fig. 1i -l). Thus, Cdk5 inhibition was necessary to robustly inhibit proliferation of cells derived 101 from multiple forms of NE neoplasms. These data indicate that Cdk5 and p35/25 expression characterize at 102 least a portion of all NE neoplasms and aberrant Cdk5 activity is a major contributor to the growth of NE 103 cancer cells.
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Downstream targets of Cdk5
105
To determine which pathways Cdk5 may target to drive NE cell proliferation, we used a unique bi-106 transgenic mouse model of MTC (NSE-p25OE mice), developed in our laboratory, in which tumors arise at 107 the natural organ site in the presence of an intact immune system. These mice express an activator of Cdk5, phosphorylation sequence (S/T-P-x-K/H/R) were eliminated. From the remaining proteins, 50 of the most 119 highly upregulated phosphorylation sites, with preference for those with established or suggested roles in 120 cancer, were selected for investigation as potential tumorigenic regulators (Ext. Data Table 2 ). Short 121 interfering peptides (SIPs) containing the phosphorylation site flanked by 8 amino acids on both the N-and 122 C-terminal sides were designed to selectively interfere with phosphorylation or function of the 50 targets. A 123 cell penetrating sequence (RQIKIWFQNRRMKWKK) from penetratin (PEN) was added to the N-terminus 124 of peptides to facilitate entry into cells. A high-throughput proliferation-based assay identified 15 SIPs that 125 inhibited growth of NE cancer cells but not normal primary fibroblasts ( Fig. 2e-f indicating that these novel sites were important for NE cancer cell growth. 127 We performed Ingenuity Pathway Analysis (IPA) to ascertain major signaling cascades and pathways 128 that are associated with these 15 proteins. Among the predicted 25 statistically enriched canonical pathways, 129 cell cycle regulation, DNA repair, and diverse cancer signaling pathways are a predominant feature ( Fig. 2f 130 and Ext. Data Table 3 ). Thus, the downstream targets identified here are associated with common cancer 131 mechanisms.
132
Biomarkers of Cdk5 activity 133
Phosphorylation state-specific antibodies were generated for detection of 6 novel sites (Ser608 ASXL2, 134 Thr143 FAM53C, Thr709 FLNB, Thr202 LARP6, Ser110 KNL2, and Ser988 RBL1) and two sites 135 previously identified as targets of Cdk2 (Ser17 H1B 23,24 and Ser391 SUV39H1 25 ) (Ext. Data Fig. 2 ).
136
Phosphorylation of these sites, as well as the thoroughly established Ser807/Ser811 sites on RB 26,27 , was 137 confirmed in mouse MTC tumors, in which growth was driven by expression of p25-GFP, and reduced in 138 arrested tumors ( Fig. 3a ). In agreement, phosphorylation levels of 6 of these sites were dose-dependently 139 decreased by the Cdk4/5 inhibitor Indo A in hPheo1 cells (Fig. 3b ). Similar decreases in these 140 phosphorylation sites were observed in human MTC-SK, TT, and BON cells (Ext. Data Fig. 3 ). This effect 141 appeared Cdk5-specific as addition of the Cdk4 inhibitor Indo B to multiple NE cell lines had significantly 142 less effect on the phosphorylation states of Thr143 FAM53C, Thr709 FLNB, Ser17 H1B, and Thr202 LARP6 compared to Indo A. In contrast, phosphorylation of Ser807/Ser811 RB, a known target of multiple 144 Cdks, was decreased upon treatment with both inhibitors. Interestingly, the phosphorylation of the RB family 145 member, RBL1, was more responsive to Indo A than Indo B in TT cells whereas phosphorylation of Ser391 146 SUV39H1 was more responsive to Indo A than Indo B in BON cells (Ext. Data Fig. 3 ). Overall, these data 147 demonstrate that phosphorylation of these 6 proteins is dependent upon Cdk5 activity and suggests that these 148 phosphorylation sites could serve as biomarkers of many types of Cdk5-driven NE tumors.
149
To determine if these Cdk5-dependent biomarkers occurred in human NE tumors, cohorts of MTC days for two weeks. Tumor growth was significantly reduced by 20 and 30 mg/kg of Indo A compared to control animals. Plasma levels of CEA, a marker of MTC 28 , were also reduced in treated animals, indicating 169 therapeutic efficacy ( Fig. 4c ). As a second model, TT cells derived from a familial case of human MTC were 170 used to generate xenograft tumors in nude mice. As with the transgenic model, Indo A attenuated TT cell 171 tumor progression ( Fig. 4d-e ). While CEA was not detected in the plasma of these animals, levels of 172 chromogranin A (ChA), another marker of MTC 29 , were reduced ( Fig. 4f ). Thus, Cdk5 inhibition blocks the 173 growth of tumors in distinct models of MTC. The efficacy of Indo A was also assessed in a xenograft tumor 174 model generated from human pancreatic NE tumor derived BON cells (Ext. Data Fig. 5 ). Indo A was equally 175 effective in impeding the growth of these tumors, suggesting that targeted Cdk5 therapy could be effective 176 across multiple NE cancer types.
177
Biomarkers are predictive of response to anti-Cdk5 therapy 178 We hypothesized that the phosphorylation states of a newly identified set of proteins could serve as encapsulated drug compared to free drug at these lower dosage levels ( Fig. 4l ).
210
Indo A delivered at 10 mg/kg BW in the free form had no effect on tumor growth in transgenic MTC 211 animals ( Fig. 4b) . In contrast, delivering only 5 mg/kg BW Indo A encapsulated in LKs had the same effect 212 as delivering 20 mg/kg BW free drug ( Figs. 4b and 4m ). Thus, the LK delivery system generated an 213 equivalent effect utilizing a 75% lower dosage. LKs also protected animals against hepatic and renal toxicity 214 ( Fig. 4n-o) . While complete tumor arrest or shrinkage was not observed at 5 mg/kg BW, further 215 modifications to allow higher encapsulation of drug could provide additional benefit for this unique delivery 
233
As with all cancers, many mutations, in addition to RET, are present within each MTC cancer cell.
234
These additional mutations can alter the diverse input nodes of the signaling network that drive cancer cell 235 growth and survival. For these reasons, looking at the signaling network with a broader lens that includes 236 post-translational modifications could be beneficial and aid in the elimination of "false positive" non-237 responders that would be predicted responders from genomic or proteomic information alone. By assessing 238 signaling states across a network of pathways, such an approach might also allow for more accurate stage-239 dependent therapeutic assessments to be made for individual patients. The current study reveals that Cdk5 is 240 likely a contributor to at least a portion all NE tumor types. It also identifies a set of phosphorylation-based biomarkers which indicate that not only are Cdk5 pathway components present, but Cdk5 is actively 242 modulating the signaling network and regulating cancer physiology.
243
In addition to being biomarkers of Cdk5 pathway activity, the phosphoproteins identified in this study 244 are potentially directly involved in promotion of cell growth and/or survival. For example, RBL1 is a 245 member of the retinoblastoma (RB) family of proteins that includes the tumor suppressor RB and RBL2. The 
252
Emerging information suggests Cdk5 may play a role in non-NE cancer as well 11 . As the heterogeneity 253 between tumors of the same cancer type is becoming more apparent, the likelihood that treatment approaches Rabbits were boosted once and blood collected twice over a 5 week period for 12 months. Blood was 271 allowed to clot at 4˚C for 24 h, centrifuged at 1000 g, and plasma isolated and stored at -20˚C.
272
Phosphorylation state-specific antibodies were purified from plasma using phosphopeptide affinity columns 273 by elution with 100 mM Glycine pH 2.5 into 1 M Tris pH 8.6 (11:1 volume ratio, final 80 mM Tris pH ~7.5).
274
Antibodies were dialyzed into 50 mM Tris pH 7.6 plus 150 mM NaCl and stored at -20°C.
275
Cell culture and assays. All cells were tested and verified to be free of mycoplasma contamination. Cell 276 lines were probed for NE markers to verify identity. Cells were cultured at 37°C and 5% CO2 in a humidified (1:1) with 10% FBS. INS cells were cultured in RPMI with 10% FBS, 1 mM Na-pyruvate, 10 mM HEPES, BON and hPheo1 cells was measured 2 days after initial SIP treatment and growth of Fibro and MTC-SK 288 cells was measured 6 days after initial SIP treatment using procedures described above.
Immunoblot analysis. Cells were seeded onto 6 well dishes and allowed to recover overnight. Cells were 290 treated for 4 h with inhibitors and then lysed in 50 mM NaF and 1% SDS with brief sonication. Samples 291 were diluted to equivalent total protein concentrations in 1X Laemmli buffer and separated by SDS-PAGE. Histology. Formalin-fixed, paraffin-embedded samples were cut into 5 µm sections, deparaffinized, and 306 subjected to microwave antigen retrieval (citrate buffer, pH 6.0). Sections were then stained using standard 307 protocols for H&E or immunostained with antibodies recognizing p35/p25 (sc-820, Santa Cruz 308 Biotechnology) or Cdk5 (308-Cdk5, PhosphoSolutions). For immunostaining, sections were permeabilized 309 with 0.3% Triton X-100, quenched free of endogenous peroxidases, and blocked with 2.5% normal goat 310 serum prior to overnight incubation with primary antibodies at 4˚C. Bound primaries were detected by 311 sequential incubation with biotinylated-secondary antisera, streptavidin-peroxidase (Vector Laboratories), 312 and diaminobenzidine chromagen (DAKO) following the manufacturer's directions.
Immunoblot analysis. Tissues were crushed while frozen then lysed in 50 mM NaF and 1% SDS with brief 314 sonication. Samples were diluted to equivalent total protein concentrations in 1X Laemmli buffer and 315 separated by SDS-PAGE. Proteins were transferred onto nitrocellulose for immunoblotting as described (25% acetonitrile/75% H20), vortexed for 1 min, diluted with 25 µL of 100% ACN, followed by two cycles 329 of vortexing for 1 min and incubating at room temperature (RT) for 10 min. Samples were then diluted with 330 200 µL of 100% ACN, vortexed for 1 min, then stored at -20˚C overnight. Samples were thawed at RT for 331 ~10 min, centrifuged at 14,000 g for 10 min at 4˚C to remove cell debris, then supernatants were transferred 332 to 2 mL tinted glass vials and dried down to ~5-10 µL under argon gas at 25˚C for 25 min. Samples were 333 immediately reconstituted (adjusted to 210 µL) in 25% ACN/1% trifluoroacetic acid/74% H20 and 334 centrifuged at 14,000 g for 10 min at 4˚C to remove any residual debris. The supernatants were then 335 transferred to tinted vials prior to analysis. EGTA, 50 mM NaF, 2 mM Na orthovanidate, 10 mM Na pyrophosphate, and protease inhibitors (Sigma 397 S8820) in PBS. Tissues were frozen or fixed in 4% PFA for 24 h and submitted for paraffin embedding.
398
Human BON and TT cell xenograft mouse models were generated by implanting 5e 6 BON or TT-RLuc cells 399 subcutaneously in the NU/NU Nude Mouse (Crl:NU-Foxn1 nu ) strain from Jackson laboratories. Beginning at 400 tumor volumes of 100-450 mm 3 (average starting sizes between groups varied less than 40mm 3 ), animals 401 were treated as described above and monitored by caliper measurement for 2 weeks. Animals were sacrificed 402 and tissue processed as described above. All animals were randomly assigned to treatment groups but 403 blinding was not possible. 
418
Toxicity Assays. Prior to cardiac perfusion, blood was collected from animal subjects via retro-orbital 419 bleeding. Blood was immediately mixed with EDTA (10 mM final) then centrifuged at 1000 g for 10 min at 420 4˚C to allow isolation of plasma. AST assays (Sigma MAK055) and Urea assays (Sigma MAK006) were 421 performed on plasma per the manufacturer's instructions. 422 We thank Melanie Cobb, Joseph Goldstein, John Minna, Roswitha Pfragner, and Courtney Townsend for 
